Therefore, ongoing prospective trials such as EMPA-AF (NCT04583813) and DAPA-AF (NCT05174052), which are explicitly designed to assess arrhythmic endpoints, will be instrumental in clarifying the rhythm-modifying potential of SGLT2 inhibitors and guiding evidence-based clinical decision-making in diabetes-associated AF. The gene discussed is SLC5A2; the disease is diabetes mellitus.